Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Common Stock
2024-01-25+317,800→ 4,513,203 total - Award
Stock Option (Right to buy)
2024-01-25+1,123,535→ 1,123,535 totalExercise: $3.20Exp: 2034-01-25→ Common Stock (1,123,535 underlying)
Holdings
- 1,201,108(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Includes 1492 shares of the Issuer's common stock acquired by the reporting person on September 15,2023 pursuant to an employee stock purchase program.
- [F2]Securities held in the name of the Chang 2006 Family Trust
- [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F5]1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.